Experimental drug voruciclib tested in desperate blood cancer patients
NCT ID NCT03547115
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was to check safety and find the right dose. The study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- voruciclib (alone or with venetoclax)
- What this could lead to
- If it works, this could point toward a new treatment option for people with blood cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not proof of effectiveness. The trial was terminated early, so results may be limited. Side effects and lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27705, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
New York University
New York, New York, 10016, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chemo-free cocktail tame mantle cell lymphoma?
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug combo aims to boost lymphoma treatment
- Supercharged immune cells take aim at cancer and viruses in one shot